Julio C. Chávez
YOU?
Author Swipe
View article: Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)
Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL) Open
Background and Significance: Cutaneous T-cell lymphoma (CTCL) is a rare, incurable non-Hodgkin lymphoma characterized by progressive Th2 immune skewing, loss of tumor surveillance, and chronic skin inflammation. Interferon-alpha (IFN-α) ha…
View article: Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma
Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma Open
Background. ZUMA-12 (NCT03761056), a multicenter phase 2 study, evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as part of first-line treatment in patients with high-risk large…
View article: Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).
Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL). Open
Introduction CAR T cells have changed the treatment landscape of relapse/refractory (RR) DLBCL, offering a curative option. About half of the patients will not be cured with CAR-T and will experience poor outcomes. One potential mechanism …
View article: Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas
Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas Open
Introduction CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy is approved as second-line treatment for aggressive B-cell lymphoma (aBCL), while CD20xCD3 bispecific antibodies (BsAbs) are approved in the third-line setting. Al…
View article: Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Open
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrol…
View article: Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers
Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers Open
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies, including lisocabtagene maraleucel, axicabtagene ciloleucel, and tisagenlecleucel, have revolutionized the treatment landscape for patients with hematologic malignancies. Ho…
View article: Hybrid Conjugates of Ibuprofen and 3,5‐Diarylidene‐4‐Piperidone: A New Avenue in Anti‐Inflammatory Drug Discovery
Hybrid Conjugates of Ibuprofen and 3,5‐Diarylidene‐4‐Piperidone: A New Avenue in Anti‐Inflammatory Drug Discovery Open
Nonsteroidal anti‐inflammatory drugs (NSAIDs) have been crucial in managing inflammation, pain, and fever since their introduction in 1897. Despite their widespread use, NSAIDs often face limitations due to gastrointestinal side effects fr…
View article: Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL
Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL Open
Chronic lymphocytic leukemia (CLL) presents challenges in treatment despite advancements in targeted therapies, often facing resistance or relapse. Chronic inflammation plays a significant role in CLL biology, with heightened inflammatory …
View article: Supplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
View article: Supplementary Table S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S4: Mixed model coefficient estimates for SMI and total adipose tissue with sarcopenia status and time points.
View article: Supplementary Figure S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Figure S3: Longitudinal Changes in Skeletal Muscle Index (SMI) Stratified by Gender and Sarcopenia Status Pre- and Post-CAR T-cell Therapy.
View article: Supplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S7 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S7: Comparison of Cytokine expansion in Sarcopenic vs. Non-sarcopenic Individuals and Association with SMI Loss.
View article: Supplementary Figure S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Figure S1: Survival Analysis by Baseline BMI Category.
View article: Supplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.
View article: Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing Open
Background Autologous CD19 chimeric antigen receptor (CAR) T-cell therapy leads to durable responses and improved survival in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Among approved CAR T-cell products, axicab…
View article: Supplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
View article: Supplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
View article: Supplementary Table S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S3 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S3: Body Composition of Patients Who Experienced Non-Relapse Mortality (NRM).
View article: Supplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S4 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Figure 4: PFS and OS Stratified by Sarcopenia and SMI Loss Status at Day 30 and Day 90.
View article: Supplementary Table S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S1 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S1: Univariable analysis of characteristics associated with Overall Survival (OS) and Progression Free Survival (PFS).
View article: Data from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Data from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Purpose:Sarcopenia is a hallmark of cancer cachexia. Chimeric antigen receptor (CAR) T-cell therapy is associated with an inflammatory state that may exacerbate sarcopenia. The relationship among CAR T-cell therapy, sarcopenia, and metabol…
View article: Supplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma Open
Supplementary Table S6: Association of corticosteroids and SMI loss.
View article: Joint position on vitamin D prescription in the adult Mexican population by AMMOM, AMEC, AMG, CMIM, CMO, CMR, CONAMEGER, FEMECOG, and FEMECOT
Joint position on vitamin D prescription in the adult Mexican population by AMMOM, AMEC, AMG, CMIM, CMO, CMR, CONAMEGER, FEMECOG, and FEMECOT Open
Background Vitamin D deficiency remains a critical health concern linked to skeletal disorders such as osteoporosis, osteomalacia, and fractures. Recent evidence highlights the broader role of vitamin D in preventing chronic conditions, in…